Addenda Capital Inc. Has $7.45 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Addenda Capital Inc. raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 31.3% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 30,123 shares of the medical instruments supplier’s stock after buying an additional 7,178 shares during the quarter. Addenda Capital Inc.’s holdings in Becton, Dickinson and Company were worth $7,454,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. Norges Bank acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at approximately $761,798,000. Vanguard Group Inc. grew its holdings in shares of Becton, Dickinson and Company by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after purchasing an additional 516,427 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of Becton, Dickinson and Company by 28.5% during the 3rd quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock worth $553,121,000 after purchasing an additional 473,914 shares in the last quarter. Morgan Stanley grew its holdings in shares of Becton, Dickinson and Company by 4.5% during the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock worth $2,637,062,000 after purchasing an additional 435,168 shares in the last quarter. Finally, Cooke & Bieler LP grew its holdings in shares of Becton, Dickinson and Company by 117.1% during the 4th quarter. Cooke & Bieler LP now owns 710,932 shares of the medical instruments supplier’s stock worth $173,347,000 after purchasing an additional 383,485 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BDX. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Thursday. The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 target price for the company. Finally, Barclays raised their target price on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $280.17.

Insider Buying and Selling

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the transaction, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at $472,876.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Roland Goette sold 3,300 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $236.73, for a total value of $781,209.00. Following the sale, the executive vice president now directly owns 11,308 shares in the company, valued at $2,676,942.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares in the company, valued at $472,876.56. The disclosure for this sale can be found here. Insiders sold a total of 8,615 shares of company stock valued at $2,033,381 over the last three months. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.2 %

Shares of BDX stock traded up $2.77 on Friday, reaching $233.71. 2,100,394 shares of the stock were exchanged, compared to its average volume of 1,453,708. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. Becton, Dickinson and Company has a one year low of $224.00 and a one year high of $287.32. The stock has a 50 day moving average price of $234.36 and a 200 day moving average price of $237.84. The stock has a market cap of $67.54 billion, a PE ratio of 51.48, a P/E/G ratio of 2.03 and a beta of 0.44.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same period in the previous year, the firm earned $2.86 earnings per share. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. Equities research analysts forecast that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be paid a dividend of $0.95 per share. The ex-dividend date is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.